×
Hero Background

Hyperglycemia Treatment Companies

ID: MRFR/HC/3146-HCR
200 Pages
Rahul Gotadki
October 2025

Many pharmaceutical companies develop and produce medications specifically targeting hyperglycemia. Companies involved in hyperglycemia treatment focus on developing, manufacturing, and distributing medications, devices, and therapies aimed at managing high blood sugar levels, particularly in conditions like diabetes. Their efforts encompass a range of solutions dedicated to regulating and improving high glucose levels for individuals affected by hyperglycemia.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Hyperglycemia Treatment Market Research Report-Forecast to 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Hyperglycemia Treatment Market

Hyperglycemia Treatment Key Companies

 

Latest Hyperglycemia Treatment Companies Update


Tandem Diabetes Care (US) Launched their Control-IQ™ technology with automated insulin dosing features in Europe, expanding their reach for patients with type 1 diabetes.Partnered with leading diabetes clinics and healthcare providers to improve patient access to their advanced insulin pump systems.


Medtronic plc (Ireland) Received FDA approval for their MiniMed 780G insulin pump system with SmartGuard™ technology for automated correction boluses, offering enhanced blood sugar control for type 2 diabetics.Focused on developing next-generation artificial pancreas systems with closed-loop insulin delivery for personalized diabetes management.


Novo Nordisk A/S (Denmark) Introduced their new long-acting GLP-1 receptor agonist, Ozempic®, in a convenient once-weekly dosing option, enhancing treatment adherence for patients with type 2 diabetes.Announced research initiatives exploring the potential of GLP-1 agonists for treating other metabolic conditions like obesity and non-alcoholic fatty liver disease.


Eli Lilly and Company (US) Received FDA approval for their SGLT2 inhibitor Jardiance® for the treatment of heart failure with preserved ejection fraction (HFpEF), expanding its therapeutic applications beyond diabetes.Collaborated with academic institutions to investigate the potential of SGLT2 inhibitors for cardiovascular protection and renal disease prevention.


Boehringer Ingelheim (Germany) Launched their oral SGLT2 inhibitor Jardiance® in a fixed-dose combination with metformin, offering a one-pill solution for patients with type 2 diabetes requiring multiple medications.Focused on developing innovative combination therapies to simplify treatment regimens and improve adherence for diabetes management.


List of Hyperglycemia Treatment Key Companies in the Market



  • Novo Nordisk A/S

  • Merck & Company Inc.

  • Medtronic

  • Johnson & Johnson Services Inc.

  • Teva Pharmaceuticals Ltd.

  • Eli Lilly and Company

  • Sanofi S.A.

  • Home Diagnostics

  • Bayer AG

  • Bristol-Myers Squibb.

  • Abbott.